Home › Drug Codes › J Codes › J1289 · Yartemlea
Updated October 1st, 2026

Yartemlea J Code: J1289

Injection, narsoplimab-wuug, 1 mg

Login to unlock all benchmarks
Medicare Payment Limit ?
$105.441
/ HCPCS billing unit
APC Payment Limit ?
$105.441
/ HCPCS billing unit · APC 0938
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
1
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Injection, narsoplimab-wuug, 1 mg
HCPCS Added Date July 1, 2026
Manufacturer Rayner Surgical
Route of Administration Intravenous
Generic Status Single-Source; Branded
Dosage Form Injection

About Yartemlea

Yartemlea is a medication aligned to the HCPCS J Code: J1289 for billing, pricing, and reimbursement purposes in the United States. Classified under Immunology, it is administered via the intravenous route and manufactured by Rayner Surgical.

Manufacturers, reach out to us to add more information.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
62225-0300-00 Yartemlea Omeros Corporation 370 370 MG / 2 ML
Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

Yartemlea Pricing & Reimbursement

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q4 2026

Yartemlea CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

Yartemlea Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.

Frequently Asked Questions

Is there an available Yartemlea billing and coding guide?
A manufacturer-published billing and coding guide for YARTEMLEA was not found.
Are there any available Yartemlea patient assistance programs?
YARTEMLEA patient assistance information can be found through OMEROS. Visit Here →
Where can I find Yartemlea prescribing information?
YARTEMLEA prescribing information can be found at the link below: Visit Here →
Where can I find Yartemlea side effect information?
Information regarding YARTEMLEA's side effects can be found at MedlinePlus Visit Here →
Does billing YARTEMLEA require JZ/JW wastage modifiers?
This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.